NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.
Banerjee, an assistant professor at the University of Washington, highlights two studies, including one prospective randomized trial of long-term outcomes of treatment with continuous lenalidomide/dexamethasone vs. MEL140 with autologous blood stem cell transplantation and one phase 1 study of GC012F chimeric antigen receptor T-cell therapy as potential first-line
